Medica Partners

About Us

Big Dreams, Daring Vision and Exciting Ideas

Innovation can create paradigm shifts in healthcare, along with significant financial returns for investors. With over 100 years of experience, Medica knows that this requires building a solid business on a platform of experience, discipline and capital. We validated this with a track record of an average 3x return over many exits.

Medica pioneered healthcare investing in Israel beginning in 1995 and has provided investment capital to support companies developing breakthrough products including first and second generation percutaneous heart valves, (PVT & Ventor; acquired by Edwards LifeSciences and Medtronic) and desktop computed radiography (Orex – acquired by Kodak). With experience in all stages of company formation and growth, Medica recognizes the ‘diamond in the rough’ which less experienced investors ignore. We help develop it and bring it to the market to deliver superior returns to our investors.

We invest in:

Private and Public companies

Companies with initial revenues
in need of growth capital

Financially distressed companies with proven technology

Companies based in the US, Europe and Israel

Companies in need of the next stage of management to
facilitate growth

Medica Partners

Management Team

Ehud Geller, Founder & Managing Partner

Co-founded Medica in 1995; veteran of
the US and Israeli healthcare industries
for over 30 years
Previously CEO of Ikapharm, CEO of Interpharm and EVP of Teva Pharmaceuticals Group
Former head of the Israeli Pharmaceutical Manufacturers Association and Tel Aviv Stock Exchange board member

Eli Hazum, General Partner

Joined Medica in 1995; scientific background – ex Weizmann Institute Professor
Previously with Glaxo – head of
metabolic disease drug development
Successful operating experience –
Collgard, Ester, PainReform

Henry Kay, Partner

Over 35 years of healthcare industry experience in marketing and strategic planning executive positions
Previously Group VP at Boston
Scientific Corp
Former Senior VP, Sales & marketing,
at Allergan Europe

Yoav Waizer, Partner & CFO

Joined Medica in 2005
Senior financial and business
research analysis
Investment experience since 1994;
Star, Cedar

Medica Partners

Next generation medical aesthetic devices for skin rejuvenation, wrinkle reduction and skin tightening; OnePulse and 3Deep technologies, provide multilayer, targeted & controlled desired clinical effects.

Unique aortic valve prosthesis designed
for easy, minimally invasive implantation, improved anchoring and superior hemodynamic performance.
Acquired by Medtronic in Feb.2009.

Specialized catheter-based delivery
systems for interventional cardiovascular procedures; Deliver, Lock, and Deploy devices anywhere on any guidewire. Acquired by Allium Medical

Cutting edge telemetric technology
enables implantable devices to communicate potential life threatening conditions.
Acquired by Boston Scientific Corporation in June 2007.

3D navigation systems (CT-guided bronchoscopy) for minimally-invasive diagnosis and treatment of lung disease.
Acquired by Covidien in May 2012

TempostatinTM - novel therapy for
cancer, restenosis & fibrosis.
Acquired by Halo Therapeutics

Revolutionary products for minimally-invasive replacement of heart valves.
Acquired by Edwards Life Sciences
in February 2004.

Diagnostics products for chronic diseases: World leader in blood glucose monitoring for diabetes.
Acquired by J&J.

Reformulated products to enhance efficacy, reduce adverse effects and increase convenience for pain treatment.

GelrinTM device for cartilage and other tissue repair.

Novel, proprietary, solutions for Spinal Stabilization and Long Bone Fracture Fixation. Product solutions address both previously unsolved surgical problems
and underserved markets.

Global leader in medical and aesthetic lasers and light-based technology for treatment of medical and cosmetic conditions.

Minimally invasive intravascular systems for targeted renal therapy.
Acquired by AngioDynamics in January 2009.

Desktop computed radiography: no films, no chemicals, PC based.
Acquired by Kodak in March 2005.

Developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders. IPO: NASDAQ: MEMY, April 2004.
Acquired by Roche in December 2008.

Technology for disease targeting agents and gamma detecting medical devices designed to provide surgeons with the location of hidden cancer during surgery.
Company was subsidiary of NASDAQ: NEOP.OB.

Innovative drug delivery solutions for the pharmaceutical and skincare industries, using proprietary technology for microencapsulation in silica.